Evaluation of the Adulticidal Efficacy of Imidacloprid 10 %/Moxidectin 2.5 % (w/v) Spot-on (Advocate®, Advantage® Multi) against Dirofilaria repens in Experimentally Infected Dogs (Q41119186)

From Wikidata

Jump to navigation Jump to search

scientific article published on August 2015

Language	Label	Description	Also known as
English	Evaluation of the Adulticidal Efficacy of Imidacloprid 10 %/Moxidectin 2.5 % (w/v) Spot-on (Advocate®, Advantage® Multi) against Dirofilaria repens in Experimentally Infected Dogs	scientific article published on August 2015

Statements

scholarly article

1 reference

Europe PubMed Central

27 September 2017

Evaluation of the Adulticidal Efficacy of Imidacloprid 10 %/Moxidectin 2.5 % (w/v) Spot-on (Advocate®, Advantage® Multi) against Dirofilaria repens in Experimentally Infected Dogs (English)

1 reference

Europe PubMed Central

27 September 2017

experimental infection

1 reference

based on heuristic

inferred from title

Dirofilaria repens

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

27 September 2017

2

0 references

author name string

Gabriele Petry

1

1 reference

Europe PubMed Central

27 September 2017

Marco Genchi

2

1 reference

Europe PubMed Central

27 September 2017

Holger Schmidt

3

1 reference

Europe PubMed Central

27 September 2017

Bettina Lawrenz

5

1 reference

Europe PubMed Central

27 September 2017

Claudio Genchi

6

1 reference

Europe PubMed Central

27 September 2017

publication date

1 August 2015

1 reference

Europe PubMed Central

27 September 2017

Parasitology Research

1 reference

Europe PubMed Central

27 September 2017

114 Suppl 1

1 reference

Europe PubMed Central

27 September 2017

S131-44

1 reference

Europe PubMed Central

27 September 2017

https://scigraph.springernature.com/pub.10.1007/s00436-015-4519-7

0 references

Dirofilaria repens infection in a dog: diagnosis and treatment with melarsomine and doramectin

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Macrocyclic lactones and Dirofilaria immitis microfilariae

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Efficacy of a single topical application of Advantage Multi (= Advocate) Topical Solution (10% imidocloprid + 2.5% moxidectin) in the treatment of dogs experimentally infected with Crenosoma vulpis.

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Stable transmission of Dirofilaria repens nematodes, northern Germany

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

5 S ribosomal spacer sequences of some filarial parasites: comparative analysis and diagnostic applications.

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Elimination of Dirofilaria (syn. Nochtiella) repens microfilariae in dogs with monthly treatments of moxidectin 2.5%/imidacloprid 10% (Advocate, Bayer) spot-on

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Evaluation of the efficacy of imidacloprid 10 % / moxidectin 2.5 % (Advocate®, Advantage® Multi, Bayer) for the prevention of Dirofilaria repens infection in dogs.

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Dirofilarial infections in Europe

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Efficacy of moxidectin microsphere sustained release formulation for the prevention of subcutaneous filarial (Dirofilaria repens) infection in dogs

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Treatment of Dirofilaria repens microfilariaemia with a combination of doxycycline hyclate and ivermectin

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Evaluation of the therapeutic and preventive efficacy of 2.5 % moxidectin / 10 % imidacloprid (Advocate(®), Bayer animal health) in dogs naturally infected or at risk of natural infection by Dirofilaria repens.

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Preliminary findings on the efficacy of selamectin in the treatment of dogs naturally infected with Dirofilaria repens

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Where are we with Wolbachia and doxycycline: an in-depth review of the current state of our knowledge

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Molecular detection of Dirofilaria immitis, Dirofilaria repens and Setaria tundra in mosquitoes from Germany

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

The safety-net story about macrocyclic lactone heartworm preventives: a review, an update, and recommendations

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Heartworm disease in animals and humans

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Current surveys on the prevalence and distribution of Dirofilaria spp. in dogs in Germany

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Canine generalized demodicosis treated with varying doses of a 2.5% moxidectin+10% imidacloprid spot-on and oral ivermectin: parasiticidal effects and long-term treatment outcomes.

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Discrimination between six species of canine microfilariae by a single polymerase chain reaction.

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Use of moxidectin tablets in the control of canine subcutaneous dirofilariosis

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Use of an injectable, sustained-release formulation of moxidectin to prevent canine subcutaneous dirofilariosis

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Human and animal dirofilariasis: the emergence of a zoonotic mosaic

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Canine and human Dirofilaria infections in the Balkan Peninsula

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Efficacy of a single administration of a spot-on solution containing imidacloprid 10%/moxidectin 2.5% in eliminating Dirofilaria repens microfilariae in naturally infected dogs

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Potential efficacy of monthly administrations of spot-on moxidectin 2.5%/imidacloprid 10% in the simultaneous prevention of major canine filarioses.

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Pharmacokinetics and dose proportionality of oral moxidectin in beagle dogs

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

Efficacy of long-term monthly administration of ivermectin on the progress of naturally acquired heartworm infections in dogs

1 reference

https://api.crossref.org/works/10.1007%2FS00436-015-4519-7

21 January 2018

World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.) guidelines for evaluating the efficacy of anthelmintics for dogs and cats

1 reference

https://pubmed.ncbi.nlm.nih.gov/26152414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prevention of Dirofilaria repens infection with ivermectin/pyrantel chewables.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26152414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of therapy by using advocate spot-on combination (imidacloprid 10% and moxidectin 2.5%) on subcutaneous dirofilariosis in dogs

1 reference

https://pubmed.ncbi.nlm.nih.gov/26152414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experimental maintenance of Dirofilaria repens and D. immitis in dogs

1 reference

https://pubmed.ncbi.nlm.nih.gov/26152414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Efficacy of ivermectin in preventing Dirofilaria repens infestation in dogs naturally exposed to contagion]

1 reference

https://pubmed.ncbi.nlm.nih.gov/26152414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ivermectin against larval stages of Dirofilaria repens in dogs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26152414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Field clinical study evaluating the efficacy and safety of an oral formulation containing milbemycin oxime/praziquantel (Milbemax®, Novartis Animal Health) in the chemoprevention of the zoonotic canine infection by Dirofilaria repens.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26152414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First autochthonous case of canine ocular Dirofilaria repens infection in Germany

1 reference

https://pubmed.ncbi.nlm.nih.gov/26152414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A case of autochthonous human Dirofilaria infection, Germany, March 2014.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26152414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00436-015-4519-7

1 reference

Europe PubMed Central

27 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

27 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41119186&oldid=2094075781"